Literature DB >> 23319568

Clonal architecture of chronic myelomonocytic leukemias.

Raphaël Itzykson1, Olivier Kosmider, Aline Renneville, Margot Morabito, Claude Preudhomme, Céline Berthon, Lionel Adès, Pierre Fenaux, Uwe Platzbecker, Olivier Gagey, Philippe Rameau, Guillaume Meurice, Cédric Oréar, François Delhommeau, Olivier A Bernard, Michaela Fontenay, William Vainchenker, Nathalie Droin, Eric Solary.   

Abstract

Genomic studies in chronic myeloid malignancies, including myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS), and MPN/MDS, have identified common mutations in genes encoding signaling, epigenetic, transcription, and splicing factors. In the present study, we interrogated the clonal architecture by mutation-specific discrimination analysis of single-cell-derived colonies in 28 patients with chronic myelomonocytic leukemias (CMML), the most frequent MPN/MDS. This analysis reveals a linear acquisition of the studied mutations with limited branching through loss of heterozygosity. Serial analysis of untreated and treated samples demonstrates a dynamic architecture on which most current therapeutic approaches have limited effects. The main disease characteristics are early clonal dominance, arising at the CD34(+)/CD38(-) stage of hematopoiesis, and granulomonocytic differentiation skewing of multipotent and common myeloid progenitors. Comparison of clonal expansions of TET2 mutations in MDS, MPN, and CMML, together with functional invalidation of TET2 in sorted progenitors, suggests a causative link between early clonal dominance and skewed granulomonocytic differentiation. Altogether, early clonal dominance may distinguish CMML from other chronic myeloid neoplasms with similar gene mutations.

Entities:  

Mesh:

Year:  2013        PMID: 23319568     DOI: 10.1182/blood-2012-06-440347

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  105 in total

Review 1.  Why methylation is not a marker predictive of response to hypomethylating agents.

Authors:  Maria Teresa Voso; Valeria Santini; Emiliano Fabiani; Luana Fianchi; Marianna Criscuolo; Giulia Falconi; Francesco Guidi; Stefan Hohaus; Giuseppe Leone
Journal:  Haematologica       Date:  2014-04       Impact factor: 9.941

2.  Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event.

Authors:  M Jawhar; J Schwaab; S Schnittger; K Sotlar; H-P Horny; G Metzgeroth; N Müller; S Schneider; N Naumann; C Walz; T Haferlach; P Valent; W-K Hofmann; N C P Cross; A Fabarius; A Reiter
Journal:  Leukemia       Date:  2015-01-08       Impact factor: 11.528

3.  Guest Editorial: Understanding of MPN and MDS/MPN based on molecular pathogenesis and clinical aspects.

Authors:  Hironori Harada
Journal:  Int J Hematol       Date:  2017-04-26       Impact factor: 2.490

4.  TET2 mutations were predictive of inferior prognosis in the presence of ASXL1 mutations in patients with chronic myelomonocytic leukemia.

Authors:  Yajuan Cui; Hongyan Tong; Xin Du; Bing Li; Robert Peter Gale; Tiejun Qin; Jinqin Liu; Zefeng Xu; Yue Zhang; Gang Huang; Jie Jin; Liwei Fang; Hongli Zhang; Lijuan Pan; Naibo Hu; Shiqiang Qu; Zhijian Xiao
Journal:  Stem Cell Investig       Date:  2016-09-23

5.  ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia.

Authors:  Eric Padron; Sean Yoder; Sateesh Kunigal; Tania Mesa; Jamie K Teer; Najla Al Ali; Mikkael A Sekeres; Jeffrey S Painter; Ling Zhang; Jeffrey Lancet; Jaroslaw P Maciejewski; Pearlie K Epling-Burnette; Eduardo Sotomayor; Rami S Komrokji; Alan F List
Journal:  Blood       Date:  2014-06-05       Impact factor: 22.113

Review 6.  Making Sense of Prognostic Models in Chronic Myelomonocytic Leukemia.

Authors:  Aziz Nazha; Mrinal M Patnaik
Journal:  Curr Hematol Malig Rep       Date:  2018-10       Impact factor: 3.952

Review 7.  Chronic myelomonocytic leukemia prognostic classification and management: evidence base and current practice.

Authors:  Dorothée Selimoglu-Buet; Eric Solary
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

8.  Physiological Srsf2 P95H expression causes impaired hematopoietic stem cell functions and aberrant RNA splicing in mice.

Authors:  Ayana Kon; Satoshi Yamazaki; Yasuhito Nannya; Keisuke Kataoka; Yasunori Ota; Masahiro Marshall Nakagawa; Kenichi Yoshida; Yusuke Shiozawa; Maiko Morita; Tetsuichi Yoshizato; Masashi Sanada; Manabu Nakayama; Haruhiko Koseki; Hiromitsu Nakauchi; Seishi Ogawa
Journal:  Blood       Date:  2017-11-16       Impact factor: 22.113

Review 9.  Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia.

Authors:  Aline Renneville; Mrinal M Patnaik; Onyee Chan; Eric Padron; Eric Solary
Journal:  Leukemia       Date:  2021-06-26       Impact factor: 11.528

Review 10.  Epigenetic modulators, modifiers and mediators in cancer aetiology and progression.

Authors:  Andrew P Feinberg; Michael A Koldobskiy; Anita Göndör
Journal:  Nat Rev Genet       Date:  2016-03-14       Impact factor: 53.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.